Table 3a. Clinical characteristics of the 3 patients relapsed after treatments.
| No | Age | Gravidity | Parity | GTN type | FIGO stage | FIGO score | Metastasis | Pretreatment β-HCG | Previous GTN history | Resistant to multi-drug | Surgical indication | Preoperative chemotherapy (regimen*n.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 23 | 1 | 0 | CC | IV | 11 | Lung, liver | 981100 | NO | YES | Chemo-resistant lesion | Other hospital*2 (5FU+Act-D*2) FAEV*2 EMA/CO*4 |
| 2 | 38 | 5 | 0 | CC | I | 11 | NO | 2383 | YES | NO | Chemo-resistant lesion | FAEV*4 EMA/CO*3 |
| 3 | 27 | 4 | 0 | CC | I | 8 | NO | 60000 | NO | YES | Persistent lesion | Other hospital*5 (PEB*3, EMA/CO*2) EMA/CO*3 |
Abbreviations: CC, choriocarcinoma; 5FU, 5fluorouracil; Act-D,dactinomycin; EMA/CO, etoposide+methotrexate+dactinomycin/cyclophosphamide+vincristine; FAEV, floxuridine+dactinomycin+vincristine+etoposide; PEB, cisplatin+etoposide+bleomycin.